New device zaps nasal nerves to stop runny nose
NCT ID NCT05591989
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a device called NEUROMARK in 80 adults with chronic rhinitis (long-term stuffy or runny nose). The device uses radiofrequency energy to disrupt nerves in the nose that trigger symptoms. The goal was to see if it safely reduces nasal symptoms like congestion and sneezing over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NEUROMARK System (a device that uses radiofrequency energy to disrupt posterior nasal nerves)
- What this could lead to
- If it works, this could offer a long-lasting, non-drug option to control chronic rhinitis symptoms.
- What could go wrong
- This was a small, single-arm study with no placebo group, so results may not be definitive. The procedure carries typical risks of nasal surgery, such as pain or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
80 people
The number who actually took part.
- Started
-
Sep 2022
- Finished
-
Aug 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Subjects MUST: 1. Be ≥18 years of age. 2. Have been experiencing rhinitis symptoms for a minimum of 6 months. 3. Have moderate to severe symptoms of runny nose (individual rTNSS symptom rating of 2 or 3), mild to severe symptoms of nasal congestion (individual rTNSS symptom rating of 1,2, or 3), and a minimum total score of 5 (out of 12) at baseline. 4. Have an allergy test (by skin prick or intradermal testing, or by a validated in vitroImmunoglobin E \[IgE test\]) on file within 5 years of the baseline visit or is willing to have one performed during the study prior to 6-month visit. 5. Be an appropriate candidate for bilateral NEUROMARK® device treatment performed under local anesthesia. 6. Test negative for active COVID-19 at the start of the study screening and continue to be free of COVID-19 symptoms until the time of enrollment/treatment. 7. Be willing and able to comply with all study elements, as indicated by written informed consent. Exclusion Criteria: Subjects MUST NOT: 1. Have clinically significant anatomic obstruction that in the investigator's opinion limit access to the posterior nose, including but not limited to severe septal deviation or perforation, nasal polyps, and/or sinonasal tumor. 2. Have had previous sinus or nasal surgery within 6 months of study enrollment. 3. Have previously undergone RF, cryotherapy, or other surgical interventions for rhinitis. 4. Have an active nasal or sinus infection. 5. Have nasal mucosal erosion/ulceration. 6. Have rhinitis symptoms that are due to seasonal allergies only. 7. Have plans to (or otherwise anticipates the need to) undergo an ENT procedure concurrently or within 6 months after the study procedure. 8. Have started a new sinonasal medication regimen within 4 weeks prior to treatment that, according to the manufacturer's labelling, has not yet stabilized. 9. Be on prescribed anticoagulants (eg, warfarin, Plavix) or ≥ 325 mg aspirin that cannot be held for an appropriate time before the procedure. 10. Have a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months. 11. Have numbness of the soft palate, excessive dry eye, excessive dry nose, or other indication of neuro/nerve compromise in the sinonasal cavity. 12. Have an active rhinitis medicamentosa or a history of rhinitis medicamentosa within the past 6 months. 13. Have been diagnosed with atrophic rhinitis. 14. Have had previous head and/or neck irradiation. 15. Have an allergy or intolerance to local anesthetic agents. 16. Be pregnant. 17. Have a physical, neurological, medical, psychiatric condition or situation that, in the investigator's opinion, puts the subject at risk, could confound the study results, or may interfere significantly with the subject's participation in the study. 18. Be participating in another clinical research study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic rhinitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alabama Nasal and Sinus Center (Alabama Allergy)
Birmingham, Alabama, 35242, United States
-
Centers for Advanced ENT Care (CAdENT)
Baltimore, Maryland, 21204, United States
-
Colorado ENT
Colorado Springs, Colorado, 80923, United States
-
Ear Nose Throat & Allergy Associates
Seattle, Washington, 98374-1145, United States
-
New Orleans Sinus Center
Marrero, Louisiana, 70072, United States
-
Richmond ENT
Richmond, Virginia, 23235, United States
-
Rontal Clinics
Royal Oak, Michigan, 48073, United States
-
Sacramento ENT
California City, California, 95661, United States
-
Specialty Physician Associates
Bethlehem, Pennsylvania, 18017, United States
-
United Medical Doctors
Temecula, California, 92592, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which steroid works better for chronic cough? a Head-to-Head trial aims to find out
- Nerve-Zapping showdown: which procedure best stops a runny nose?
- New device zaps nose nerves to stop runny nose
- Zapping nasal nerves could stop runny noses
- New gel promises Ultra-Fast relief for chronic throat and nose sufferers
- New nasal nerve device shows promise for stuffy noses